Theranos trial: Elizabeth Holmes makes surprise testimony

2 years ago 123
ARTICLE AD BOX

Image source, Getty Images

Image caption,

Elizabeth Holmes in the California court on Wednesday

An entrepreneur accused of scamming investors for millions of dollars with a bogus blood test has surprised a US court by testifying in her defence.

Elizabeth Holmes is accused of making false claims about her firm Theranos, including that its technology could detect diseases with a drop of blood.

Ms Holmes, 37, faces multiple charges of fraud and could spend years in jail if found guilty. She denies wrongdoing.

Until now jurors had not even seen her without a mask.

But, removing it to take the stand, Ms Holmes said her work at Theranos had made her believe in the company's technology.

She explained about how she founded the firm after dropping out of Stanford University, and how her team made an apparent technological breakthrough.

"We worked for years with teams of scientists and engineers to miniaturise all of the technologies in the laboratory," she told jurors.

Throughout the two-month trial, jurors in California have heard testimony from more than two dozen prosecution witnesses. They include patients and investors who prosecutors say Ms Holmes deceived.

Her decision to testify is seen as risky as prosecutors will get a chance to cross-examine her. Defendants in US criminal cases are not obliged to testify.

Ms Holmes rose to fame in 2013 thanks to technology she claimed could test for multiple diseases using just a few drops of blood from a finger prick.

She attracted high-profile investors including Rupert Murdoch but in 2015 a whistleblower revealed the tests did not work, and the billionaire fell from grace.

By 2018 Theranos had collapsed amid one of the biggest corporate scandals in recent US history.

Ms Holmes has pleaded not guilty to nine counts of wire fraud and two counts of conspiracy.

Her lawyers say she did not intend to defraud, but instead "naively underestimated" the challenges her business faced.

The trial, which began in September, is expected to run until next month.

More on this story

Read Entire Article